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Vaccination of mice with OprI-linked recombinant antigens results in mixed Th1/Th2 
immune response. 
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Abstract 25 
 26 
OprI is an outer membrane lipoprotein from Pseudomonas aeruginosa, and when fused to a 27 
recombinant antigen, will exert adjuvant properties by engaging Toll-like receptor 2, leading to 28 
dendritic cell activation. Previous studies have shown that the Neospora caninum (Nc) antigens 29 
NcPDI, NcROP2 and NcROP40 are implicated in host cell interactions and are promising 30 
vaccine candidates. In two independent experiments, the efficacy of a polyvalent vaccine 31 
formulation composed of OprI-NcPDI, OprI-NcROP2 and OprI-NcROP40 (collectively named 32 
O-Ags) was assessed in non-pregnant and pregnant Balb/c mouse models challenged with 33 
tachyzoites of the high-virulence isolate Nc-Spain7. Parameters that were investigated were 34 
clinical signs, fertility, parasite burden in adult mice, humoral and cellular immune responses at 35 
different time-points prior to and after challenge infection, vertical transmission and post-natal 36 
survival of offspring mice, all to explore potential correlations with efficacy. Vaccination of mice 37 
with O-Ags induced a mixed Th1/Th2 immune response in adult mice and led to significantly 38 
increased protection against cerebral infection. Vaccination with O-Ags also resulted in reduced 39 
vertical transmission, and postnatal disease in offspring was significantly inhibited at a rate not 40 
observed in mice infected with a high-virulence isolate to date. However, O-Ags mixed with TLR 41 
ligands targeting TLR3 and TLR7, which are known to induce clear Th1-biased responses, or 42 
vaccination with OprI fused to the non-N. caninum antigen ovalbumin (OprI-OVA) did not 43 
confer protection. 44 
 45 
 46 
Keywords: Neosporosis; mouse model; pregnancy; vaccine; dendritic cells; immunomodulation; 47 
rhoptries; protein disulfide isomerase  48 
 49 
1. Introduction 50 
Neospora caninum is a cyst-forming coccidian closely related to Toxoplasma gondii, and is 51 
one of major causes of infective abortion in cattle [1]. In addition, N. caninum infection in cattle 52 
often results in birth of weak calves or persistently infected offspring, which then transmits the 53 
parasite to the next generation. Vaccination has been considered to be the most cost-effective 54 
strategy to control bovine neosporosis [2,3], but no commercial vaccines are available [4]. 55 
Live vaccines based on attenuated N. caninum isolates partially protected mice and cattle 56 
against fetal death upon experimental challenge infection during pregnancy [5,6,7]. However, 57 
several disadvantages of live vaccines related to costs of parasite in vitro culture, storage, limited 58 
shelf life of the final product and logistics of its distribution, as well as the potential risks of 59 
virulence reversion and recombination between attenuated and circulating strains, render live 60 
vaccines a rather unattractive option [4]. Vaccines based on total antigenic extracts or different 61 
antigenic fractions of the parasite have shown variable results with overall lower success [7]. 62 
Subunit vaccines composed of recombinant antigens would represent an interesting option and 63 
would solve many of the inherent logistic and financial disadvantages of live vaccines [4]. 64 
Admittedly, recombinant vaccine formulations have so far not shown very promising effects in 65 
pregnant neosporosis animal models. However, the versatile potential of recombinant vaccines 66 
should be much more exhaustively exploited by applying antigen combinations with adjuvants 67 
targeting different components of the immune system [4].  68 
There is “proof-of-concept” that a reduction of vertical transmission and postnatal 69 
mortality due to N. caninum infection can be achieved by vaccination not only with live vaccines 70 
[8,9], but also with recombinant subunit vaccines in mice [10,11]. Bacterially expressed 71 
recNcPDI, recNcROP2 and recNcROP40 represent promising vaccine candidates. Immunization 72 
of mice with recNcROP2 formulated in saponin resulted in a significantly increased survival rate 73 
in adult mice [12] and in offspring born to mice infected during pregnancy with the N. caninum 74 
Nc-1 isolate [10]. NcROP40 is another rhoptry protein that is abundantly expressed in virulent N. 75 
caninum isolates [13]. Immunization of mice with both recNcROP40 and recNcROP2 76 
recombinant proteins lead to reduction of vertical transmission and postnatal mortality of 16% in 77 
offspring born to mice infected with the highly virulent isolate Nc-Spain7 [11]. RecNcPDI (N. 78 
caninum protein disulfide isomerase) had conferred protection against cerebral neosporosis when 79 
applied intranasally [14], but failed to protect dams and their offspring [2].  80 
The TLR2-ligand OprI is an outer membrane lipoprotein from Pseudomonas aeruginosa. 81 
It has been used to confer adjuvant properties when expressed in fusion with different antigens.  82 
[15]. Different immune functions have been attributed to TLR2 signaling including the promotion 83 
of a mixed and balanced Th1-, Th2- and Treg cell response [16] and a T-cell tropism to mucosal 84 
tissues even when inoculated via a non-mucosal route [17]. In previous immunization studies, 85 
OprI had been fused to the N. caninum chimeric antigen Mic3-1-R, and vaccinated mice were 86 
challenged during pregnancy. This did not result in protection, neither in dams nor in offspring 87 
mice, but we nevertheless detected that fusion of OprI to MIC3-1-R induced a mixed Th1/Th2 88 
profile response [18], while the immune response in mice immunized with MIC3-1-R emulsified 89 
in saponin was  largely Th2-biased, thus confirming the immunomodulatory properties of OprI-90 
fusions. This well-adjusted Th1/Th2 balance is required to protect N. caninum vaccinated mice 91 
during pregnancy when a strong Th1 response could be detrimental [30].   92 
In this study, we performed two independent experiments to assess the efficacy of a 93 
polyvalent vaccine formulation composed of OprI-NcPDI, OprI-NcROP2 and OprI-NcROP40 94 
(collectively named O-Ags) in non-pregnant and pregnant Balb/c mouse models challenged with 95 
N. caninum tachyzoites. In one of the experiments, the same O-Ags formulation was mixed with 96 
two additional TLR ligands targeting TLR3 and TLR7, which are known to induce clear Th1-97 
biased responses [19] and likewise effects in dams and offspring were assessed. In the other 98 
experiment, a group vaccinated with OprI fused to ovalbumin (OprI-OVA) was included to 99 
provide an irrelevant antigen control.  100 
 101 
2. Materials and methods 102 
 103 
2.1. Neospora caninum culture, inoculum and crude extract preparation  104 
 105 
The N. caninum Nc-Spain7 isolate [20] was grown in vitro by continuous passages in 106 
Vero cell cultures [18]. The parasite inoculum was prepared as described [21]. N. caninum crude 107 
extract for lymphocyte re-stimulation assay and Western blot, and soluble antigen fractions for 108 
ELISA, were prepared as described earlier [18].  109 
 110 
2.2. Production of recombinant antigens fused to OprI 111 
 112 
The coding sequence of NcPDI (aa 25-446) [22], a fragment of NcROP2 (aa 238-594) 113 
[12] and the complete coding sequence of NcROP40 [11] were cloned in the pOLP plasmid in 114 
frame with OprI [15]. A previously described plasmid, containing the ovalbumin (OVA) partial 115 
sequence (aa 203-386) in frame with OprI [16] was also used to obtain the unrelated antigen 116 
OprI-OVA. Proteins were all expressed in Rosetta(DE3)pLysS Escherichia coli strain (Novagen). 117 
They were isolated from the bacterial outer membranes as previously described [18]. Purified 118 
OprI-NcPDI was dialyzed against PBS over-night at 4°C and stored at -80°C. OprI-NcROP2 and 119 
OprI-NcROP40, expressed less efficiently and insoluble in aqueous solution, were dialyzed over-120 
night against 1g/L ammonium bicarbonate at 4°C and lyophilized. They were resuspended in 121 
PBS in one-tenth of the original volume, vortexed, and were sonicated at 30°C in a water bath 122 
until a homogeneous suspension was obtained. All purified OprI-antigens were finally stored at -123 
80°C. Non-OprI-fused NcPDI, NcROP2 and NcROP40 [11,22,22], were expressed and purified 124 
as described [18]. The purity and integrity of all proteins were analyzed by SDS-PAGE and the 125 
protein concentration was determined (BCA Protein Assay Kit, Thermo Scientific Pierce). 126 
Endotoxin levels were quantified by the Limulus-Amebocyte-Lysate-Kinetic-QCL (Lonza). The 127 
final LPS content was below 0.1EU/µg. 128 
 129 
2.3. Dendritic cell (DC) stimulation 130 
 131 
OprI-fused and non-fused recombinant proteins were assessed for DC stimulation [18]. 132 
Briefly, DCs were obtained in vitro from bone marrow cells obtained from a naïve Balb/c mouse. 133 
DCs (0.5x10
6 
cells/ml) were cultured in the presence of each protein (1 or 5μg/ml), LPS 134 
(0.1μg/ml) or medium during 24hours, and TNF-α was measured in the culture supernatants by 135 
ELISA [18]. 136 
 137 
2.4. Immunization schedule, clinical monitoring and sample collection 138 
 139 
All animal protocols were approved by the Bernese Animal Welfare Committee (license 140 
BE115/14.) Two experiments were carried out. Schedules of immunization, mating, blood sample 141 
collection and euthanasia for both studies are depicted in Fig.1. Six weeks-old BALB/c mice 142 
were purchased from Charles River Laboratories (Sulzfeld, Germany) and maintained as 143 
described [18].  144 
In Experiment 1, 16 to 20 female mice per group were immunized three times, at two-145 
week intervals. The O-Ags group was subcutaneously injected with all three OprI-antigens, 5µg 146 
each; the O-Ags+TLR group was immunized with the same antigens mixed with poly I:C (TLR3 147 
ligand) (Invivogen) and R848 (TLR7 ligand) (Invivogen), 25µg each. Two control groups, one of 148 
which remained non-infected throughout the experiment (C-), the other one that was infected 149 
(C+), received PBS only. Eight days after the second injection, just prior to the oestrus 150 
synchronization, a blood sample was obtained from 4 mice per group (see Fig.1; PrCh-1) and 151 
serum recovered for IgG analysis.  152 
In experiment 2, experimental groups of 20 female mice were immunized subcutaneously 153 
three times, at two-week intervals. The O-Ags group received the three antigens as above, the O-154 
OVA group was injected with 15µg of OprI-OVA, the two additional groups (C- and C+ groups, 155 
see above) received PBS. A blood sample from the tail was obtained from all mice 4 days after 156 
the third immunization (at 4-7 days post-mating) just prior to challenge (Fig.1; PrCh-2). 157 
Eight days post- second immunization, mice in both experiment 1 and experiment 2 were 158 
submitted to oestrus synchronization [23] and 2 females and 1 male per cage were mated during 159 
72h. The third immunization was applied after separation of males and females, 5 days prior to 160 
challenge infection. At 5-8 days of pregnancy, mice from the O-Ags, O-Ags+TLR, O-OVA and 161 
C+ groups were subcutaneously infected with 10
5
 Nc-Spain7 tachyzoites [24]. Mice of the C- 162 
groups received only PBS. At day 9 post-infection, a blood sample was obtained from the tail of 163 
3 pregnant mice of each group from experiment 1 and of all mice from experiment 2 (Fig.1; 164 
PstCh-pm). Two days before birth, pregnant and non-pregnant mice were separated. Dams were 165 
allowed to give birth and rear their offspring in individual cages. Non-pregnant mice were kept in 166 
groups of 4-5 mice per cage. Following infection, all mice were daily monitored for clinical signs 167 
using a standardized score sheet: coat (ruffled coat=score1; stary stiff coat=score2); weight loss 168 
(10% loss=score1, 15-20% loss=score 4); behavior (hunched appearance, walking in circles, head 169 
tilt, apathy and ataxia, all=score 1). Animal were euthanized when the score exceeded 3 points.   170 
At 30 days post-infection (30 dpi), all surviving non-pregnant mice in both experiments 171 
were euthanized (Fig.1; PstCh-NonPreg). Dams and their pups were maintained together until 172 
day 30 post-partum (pp) (=41-44 dpi), subsequently all animals were euthanized (Fig.1; PstCh-173 
D).  174 
Data on clinical signs, fertility (percentage of pregnant mice), litter size (average of 175 
number of pups born per dam), neonatal mortality of pups (stillborn pups or pups dying within 176 
the first 2 days post-partum (dpp) and postnatal mortality (pups dying between day 3 and 30pp) 177 
were recorded. Upon euthanasia, blood was extracted by cardiac puncture and sera stored at -80 178 
°C. Brains from non-pregnant mice, dams and surviving pups were also collected and 179 
immediately frozen at -20°C. Spleens from 5 to 6 non-pregnant mice and dams per group were 180 
aseptically recovered and processed for splenocyte re-stimulation in vitro. 181 
 182 
2.5.Analysis of the cerebral parasite burden 183 
 184 
Brains from non-pregnant mice, dams and surviving pups were analyzed by N. caninum-185 
specific real-time PCR [25]. DNA extraction was performed using the Nucleospin Kit 186 
(Macherey-Nagel, Oensingen, Switzerland). The DNA concentration in all samples was 187 
determined using the QuantiFluor dsDNA System (Promega, Madison, Wi.) and was adjusted to 188 
5ng/µl with sterile DNase free water. Quantitative real-time PCR was performed using the Rotor-189 
Gene 6000 real-time PCR machine. The parasite load was calculated by interpolation from a 190 
standard curve with DNA equivalents from 1000, 100 and 10 N. caninum tachyzoites included in 191 
each run. 192 
 193 
2.6. Assessment of cytokine expression levels in serum and splenic lymphocytes stimulated in 194 
vitro 195 
 196 
Levels of mouse IFN-γ, IL-10, IL-2 and IL-5 were assessed at two different time-points in 197 
experiment 2: (i) at 9dpi, coinciding with days 14-17 of pregnancy (PstCh-pm, see Fig.1) in 198 
blood, and (ii) at the late post-challenge phase in non-pregnant mice (30 dpi) and dams (43-45 199 
dpi) by splenocyte re-stimulation in vitro as described [18]. For cytokine assessment in blood, the 200 
serum samples were analysed by bead-based multiplex assay for the Luminex® platform 201 
(Hertogenbosch, The Netherlands) . Microtiter filter plates were run on Luminex instruments 202 
(Bio-Plex
TM
200 system). Calibration curves were calculated with Bio-Plex Manager software 203 
using a five-parametric logistic curve fitting [18]. For cytokine analysis upon splenocyte recall 204 
responses, spleens were disaggregated and splenocyte cell suspensions were prepared as 205 
described [18], The resulting cell suspensions were seeded in 48-well plates and re-stimulated 206 
with either concanavalin A (ConA; 5µg/ml; Sigma), recNc-PDI, NcROP2, NcROP40 (20µg/ml), 207 
whole N. caninum crude extract (10µg/ml) or remained non-stimulated. Supernatants were 208 
collected after 72h and stored at -80°C until cytokines were assessed by ELISA (BD 209 
OptEIA™ Mouse ELISA Set, LifeSpan Biosciences Inc., Seattle, WA, USA).  210 
  211 
2.7. Analysis of serum immunoglobulins  212 
 213 
Immunoglobulins were analyzed at different time-points: (i) during the pre-challenge 214 
phase prior to mating in experiment 1 (PrCh-1); (ii) during pre-challenge phase after mating in 215 
experiment 2 (PrCh-2); (iii) during the early post-challenge phase in experiments 1 and 2 (PstCh-216 
pm); (iv) at the late post-challenge phase just prior to euthanasia in non-pregnant mice (PstCh-217 
NonPreg) and in dams (PstCh-D) (see Fig.1). Serum levels of N. caninum, NcPDI-, NcROP2- or 218 
NcROP40-specific IgG1 and IgG2a were measured by ELISA [26]. Four 4-fold serial dilutions 219 
were analyzed for each sample and results were expressed as end-point titer (EPT) calculated as 220 
the inverse value of the dilution giving an OD≥cut-off [27]. The cut-off was independently 221 
positioned in each plate in the lower linear part of the dilution curve of the same positive control 222 
which allowed the normalization between plates. 223 
PrCh-1 and PstCh-pm serum samples from experiment 1 were also analyzed in pools by 224 
immunoblotting for NcROP2- and NcROP40-specific IgG. Non-OprI NcROP2 and NcROP40 225 
(10µg each) were submitted to Western blot analysis following standard procedures [26]. Pooled 226 
sera were incubated at 1:50, 1:200 and 1:800 dilutions and an anti-mouse IgG antibody 227 
conjugated to alkaline phosphatase (eBioscience) at 1:5000 dilution was employed. 228 
 229 
2.8.Statistical analysis 230 
Cytokines levels, clinical signs scores and cerebral parasite burdens were compared 231 
between groups by the non-parametric Kruskal-Wallis test; upon detection of statistical 232 
differences, a Dunn’s multiple comparison test was subsequently applied to compare pair-by-pair. 233 
End point titers of IgG1 and IgG2a or ratios IgG1:IgG2a were compared between groups by 234 
Kruskal-Wallis test followed by Dunn’s multiple comparison post-test or by Mann-Whitney U 235 
test when only two groups were compared at pre-challenge and pregnancy phases or between 236 
dams and non-pregnant mice in each group. Repeated measures of PDI antibodies along time 237 
were compared by Wilcoxon matched pairs test. Correlations between parasite burden or vertical 238 
transmission and any immune parameters were analyzed by Pearson correlation coefficient. To 239 
compare the mortality of pups along time, survival proportions at each time-point were plotted in 240 
Kaplan-Meier graphs and survival curves were compared by Log-rank test. The percentages of 241 
survivors at the end of the experiment or percentages of N. caninum PCR positive samples were 242 
analyzed by Chi-square test with Yates’ continuity correction in a contingency table. 243 
Regarding the parameters measured in both experiments and compared between groups 244 
(C-, O-Ags and C+), a unique statistical analysis was done with all data from both experiments. 245 
A mixed-effects log-linear model (Venables and Ripley, 2002) was used to analyze pregnancy 246 
and immunization with the O-Ags formulation as fixed effects on parasite burden, having 247 
experiment as random effect. Effect sizes were estimated with a penalized quasi-likelihood 248 
method (glmmPQL from MASS library). A logistic mixed model with Laplace parameter 249 
estimation via Lapplace approximation (glmer of lme4 package) was used to evaluate clinical 250 
signs presence and vertical transmission. The odds-ratio (OR) relative to the O-Ags group was 251 
calculated with the respective 95% confidence interval (CI 95%). Survival of pups was compared 252 
with a Cox model with fixed (immunization) and random (experiment) effects (coxme library). 253 
Statistical significance was established at P<0.05. 254 
 255 
3. Results  256 
 257 
3.1. Increased dendritic cell stimulation by OprI-fused recombinant antigens 258 
 259 
The purified OprI-fused recombinant proteins shown in Fig.2A were used for stimulation 260 
of bone marrow-derived DCs, which were cultured in the presence of 1 or 5 µg/ml of each 261 
protein, LPS (0.1μg/ml) or medium during 24 hours, and the production of TNF-α was measured 262 
in the culture supernatants by ELISA (Fig.2B). In contrast to the non-fused recombinant antigens, 263 
the OprI-proteins induced strong and specific DC stimulation (Fig.2B). 264 
 265 
3.2. Immunization with OprI-fused Neospora antigens reduced vertical transmission and 266 
increased postnatal survival  267 
 268 
Table 1 shows the outcome of N. caninum infection in dams and pups in both 269 
experiments. Comparing the O-Ags groups and the C+ infection control groups in both 270 
experiments, using the experiment as random effect in the mixed model, there was a significant 271 
increase in survival of offspring of O-Ags groups P <0.001) and a significant reduction in vertical 272 
transmission (OR=4.52, CI 95% [2.06;10.63],  P<0.001).  273 
Analyzing experiment 1 separately, offspring from O-Ags group also showed a significant 274 
higher survival compared to C+ (χ
2
 and Log-rank test, P <0.05). In the O-Ags+TLR group in 275 
experiment 1 (Fig.3A), the pup survival curve was also significantly different from the O-Ags 276 
group (Log-rank test, P<0.01), showing that supplementation of the O-Ags formulation by TLR3 277 
plus TLR7 ligands abolished the protective effect of O-Ags immunization.  In fact, the O-278 
Ags+TLR group the survival of pups was not significantly different from C+ (χ
2
 and Log-rank 279 
test, P >0.05) (Table 1; Fig. 3A). 280 
In experiment 2 (Fig. 3B), comparing the C+ group with the O-Ags group, the percentage 281 
of pups survival and the pup survival curves from O-Ags were also significantly higher (χ
2
 and 282 
Log-rank test, P <0.01) and the vertical transmission significantly lower than C+ (χ
2
 and Log-283 
rank test, P <0.01). Here, a group of mice was immunized with OprI fused to ovalbumin (O-OVA 284 
group). In this latter group immunized with O-OVA, the percentage of surviving pups, the pup 285 
survival curve and the vertical transmission were identical to C+ (O-OVA vs C+; χ
2
 and Log-rank 286 
test, P >0.05) (Table 1; Fig.3B). 287 
 288 
3.3. Immunization with OprI-fused Neospora antigens reduced cerebral neosporosis  289 
Taking into account both experiments in the mixed-effects logistic model there was a 290 
significant effect of O-Ags vaccination on the likelihood of animals developing clinical signs, 291 
with C+ animals at higher risk (OR=12.6, CI 95% [1.76; 260.66],  P<0.05) independent of 292 
pregnancy. A significant effect of both O-Ags immunization (P<0.001) and pregnancy (P<0.01) 293 
on the cerebral parasite burden, without a significant interaction between these two variables 294 
(P>0.05), was observed with the mixed effects log linear model (Fig.4A,B).  Compared to non-295 
immunized mice (C+), O-Ags vaccinated dams showed lower parasite burdens.  296 
In experiment 1 and 2, dams immunized with O-Ags+TLR or O-OVA did not show 297 
reduced cerebral parasite burden compared to C+ (Kruskal-Wallis, P>0.05) (Fig.4A,B). 298 
Regarding non-pregnant mice, immunization with O-Ags also reduced significantly the cerebral 299 
parasite burden and clinical signs (Fig.4C,D). This could only be seen in experiment 2 (O-Ags vs 300 
C+; Kruskal-Wallis, P <0.05), since in experiment 1 only one mouse from O-Ags was not 301 
pregnant. No protective effect was observed in mice immunized with O-Ags+TLR (data not 302 
shown) or  O-OVA (Kruskal-Wallis, P>0.05) (Fig.4C). 303 
 304 
3.4. Humoral immune responses against recombinant antigens  305 
 306 
Specific antibody responses against each of the recombinant antigens used for 307 
immunization were studied by ELISA in both experiments at different time-points in the pre-308 
challenge phase, either prior to mating in experiment 1 (PrCh-1) or 5 days post-mating in 309 
experiment 2 (PrCh-2), and at 9dpi (14-16 days post-mating; PstCh-pm.). Specific anti-ROP2 and 310 
anti-ROP40 antibody levels were very low at both pre-challenge time-points and several animals 311 
remained ELISA-seronegative when assessed even at 9dpi in both experiments. Thus, pools of 312 
sera collected at the pre- and post-challenge time-points in experiment 1 were analyzed by 313 
Western blotting (Fig.5A). Anti-ROP2 antibodies remained virtually undetectable in sera taken 314 
during the pre-challenge phase in the groups immunized with O-Ags and O-Ags+TLR. However,  315 
IgG levels in O-Ags and O-Ags+TLR were higher in sera taken during pregnancy at 9 dpi 316 
(PstCh-pm), especially in the group immunized with O-Ags. Anti-ROP40 IgG levels were also 317 
low in both groups prior to challenge but were dramatically elevated in the group immunized 318 
with O-Ags+TLR in post-challenge sera taken from pregnant mice (PstCh-pm) (Fig.5A). Sera 319 
obtained from the O-OVA and the C+ group remained negative for ROP2 and ROP40 at both 320 
PrCh-1 and PstCh-pm. 321 
PDI-specific antibodies were detected by ELISA during the pre-challenge phase. In 322 
experiment 1, levels in mice vaccinated with O-Ags+TLR were higher than those in mice 323 
vaccinated with O-Ags, and in spite of the low number of samples the difference reached 324 
statistical significance for IgG2a at the pre-challenge phase in experiment 1 (PrCh-1; Mann-325 
Whitney U test, P<0.05) (Fig.5B). Moreover, the IgG1:IgG2a ratio was markedly lower in the O-326 
Ags+TLR group compared to the O-Ags group, and was statistically significant during the pre-327 
challenge phase (Mann-Whitney U test, P< 0.05) (Fig.5C). Surprisingly, PDI antibody levels 328 
were lower at 9dpi (PstCh-pm) than before mating in both vaccinated groups (Fig.5B). Since the 329 
values at 9dpi corresponded to just three pregnant animals and no identification of mice was 330 
carried out, we could not deduce the individual evolution of antibody levels in experiment 1. 331 
Thus, in experiment 2 mice were individually tracked. With the exception of one, those O-Ags-332 
vaccinated mice with confirmed pregnancy exhibited very little changes or decreased anti-PDI 333 
antibody levels during the timespan between pre-challenge to 9dpi (Wilcoxon matched pairs test; 334 
P>0.05), whereas those mice that did not become pregnant exhibited a clear boost of anti-PDI 335 
antibody levels (Wilcoxon matched pairs test, P<0.01) (suppl. Fig.1), confirming the results from 336 
experiment 1. The same tendency was observed with IgG2a levels (data not shown). Only one 337 
pregnant mouse exhibited a strong increase of antibody levels, and this animal had a very high 338 
parasite burden, elevated clinical signs score, and vertical transmission of N. caninum tachyzoites 339 
to its offspring (suppl Fig.1).  340 
 341 
3.5.Antibody responses against soluble N. caninum antigens  342 
 343 
No significant differences in IgG1 or IgG2a levels between groups were detected (Kruskal-344 
Wallis, P>0.05) (Fig.6). In sera from mice immunized with O-Ags, and O-OVA, and from 345 
infected non-immunized C+ mice, similar IgG2a levels were noted in dams and non-pregnant 346 
mice (Mann-Whitney U test, P>0.05), whereas IgG1 levels were significantly lower in non-347 
pregnant mice compared to dams (Mann-Whitney U test, P<0.05) pointing towards an IgG2a-348 
biased response in non-pregnant mice compared to dams. In contrast, in sera of mice vaccinated 349 
with O-Ags+TLR ligands, no such differences between dams and non-pregnant were detected 350 
(Mann-Whitney U test, P>0.05), and the humoral immune response was IgG2a-biased in both 351 
cases (Fig. 6). 352 
  353 
3.6.Cytokine responses  354 
 355 
Cytokines were measured in experiment 2 at 9dpi in peripheral blood and at the end of the 356 
experiment upon in vitro stimulation of splenocytes and analysis of culture supernatants. At 9dpi, 357 
the levels of IFNγ, IL-10 and IL-5 in peripheral blood were significantly elevated in all infected 358 
animals when compared to group C- (Fig.7). However, IFNγ-levels in pregnant as well as non-359 
pregnant mice vaccinated with O-Ags were significantly lower than in the C+ group (Kruskal-360 
Wallis, P<0.05). IL-10 levels were also significantly lower in non-pregnant mice vaccinated with 361 
O-Ags compared to non-pregnant mice in the C+ group. No significant levels of IL-2 were 362 
detected in peripheral blood samples of any group (data not shown). 363 
At the end of the experiment mice were sacrificed, splenocytes were cultured and cytokine 364 
recall responses were measured in medium supernatants. In non-pregnant mice, only splenocytes 365 
from O-Ags and O-OVA vaccinated mice displayed a consistent increase of IFNγ and IL-10 366 
secretion upon stimulation with N. caninum crude extract, compared to splenocytes from C- mice 367 
(Kruskal-Wallis, P<0.05) (Fig.8). Splenocytes derived from the C+ group showed no changes or 368 
very little increase of cytokine production. In the case of vaccinated dams, splenocyte cytokine 369 
levels were more heterogeneously distributed, with high individual variations, with the exception 370 
of highly elevated IL-2 responses in splenocytes isolated from O-Ags vaccinated dams, (Fig.8).  371 
 372 
 373 
4. Discussion 374 
 375 
The development of sub-unit vaccines against parasitic diseases is a major challenge due 376 
to the complexity of the biology of parasites [28]. This is especially true in the case of congenital 377 
neosporosis, for which so far only live-attenuated vaccines have achieved reasonable levels of 378 
protection against vertical transmission [29]. In the present work, an immunogenic formulation 379 
composed of three recombinant N. caninum antigens fused to OprI was assessed in a standardized 380 
pregnant mouse model of neosporosis based on the highly virulent N. caninum isolate Nc-Spain7. 381 
The vaccine formulation was composed of bacterially expressed and purified recNcPDI, NcROP2 382 
and NcROP40, all three N-terminally fused to the OprI, a tri-acylated bacterial outer membrane 383 
protein.  OprI targets TLR2, and thus stimulates mixed Th1, Th2 and Treg responses, favoring 384 
cross-presentation by APCs [16] Moreover, OprI was able to modulate the cellular immune 385 
response against N. caninum towards a mixed Th1/Th2 response in mice vaccinated with the N. 386 
caninum chimeric antigen Mic3-1-R [18]. The NcROP40 gene was found to be identical in three 387 
N. caninum isolates displaying different virulence, which renders this a promising vaccine 388 
candidate [31,32]. RecNcROP2 had been demonstrated to confer significant protection in non-389 
pregnant and pregnant neosporosis mouse models based on the N. caninum Nc1 isolate [10,12]. 390 
RecNcPDI had conferred excellent protection in non-pregnant mice when applied intranasally 391 
emulsified in cholera toxin, but failed to prevent congenital neosporosis in pregnant mice [2, 14]. 392 
Nevertheless, since TLR2-ligands have shown to induce mucosal immunity by imprinting 393 
lymphocyte tropism to mucosae, even though they are applied by non-mucosal route [17], and 394 
NcPDI had conferred mucosal immunity [14], we incorporated this protein into the polyvalent O-395 
Ags formulation. 396 
We show here in two independent experiments that immunization with O-Ags confers 397 
significant protection in offspring born to dams that were challenged with N. caninum tachyzoite 398 
infection on day 7-9 of pregnancy. Postnatal mortality was reduced by 25.0 and 26.9% of pups in 399 
experiment 1 and 2, respectively, the mean survival time was extended and, overall, there was a 400 
clear difference in the survival curves.  This rate of protection against congenital neosporosis has 401 
not been seen with recombinant antigens before (11). Vertical transmission (including dead pups 402 
and PCR positive survivors) was reduced in 17.2 and 24.4% of pups, respectively, showing a 403 
significant effect of immunization. In addition, vaccinated dams and non-pregnant mice exhibited 404 
significantly less parasite burden, compared to the corresponding control groups, and the 405 
likelihood of developing clinical signs was strongly reduced, with non-vaccinated animals at 406 
higher risk. 407 
In contrast to vaccination protocols applied earlier [2,10,11], the third immunization was 408 
applied just after males and females were separated, 5 days prior to challenge infection. This 409 
immunization protocol was safe and did not impair pregnancy. Applying the final immunization 410 
during, rather than prior to, pregnancy could favor an immune response that is adequate for 411 
pregnancy maintenance without losing efficacy against N. caninum infection, as shown for 412 
several human vaccines [33].  413 
The protection induced by immunization of mice with O-Ags was abrogated by adding 414 
the TLR-3 ligand Poly I:C and the TLR7-ligand R848 as additional adjuvants. Thus, the 415 
protection observed was associated with the particular OprI-adjuvant effect. TLR3 and TLR7 are 416 
potent inducers of a Th1-type response [34]. In experiment 1, the O-Ags+TLR group exhibited 417 
hallmarks of a strongly Th1-biased immunity. The more balanced Th1/Th2 immunity elicited 418 
through O-Ags was more favorable for successful pregnancy. In addition, the complete absence 419 
of protection in mice immunized with OprI-fused ovalbumin, and our previous studies employing 420 
a chimeric N. caninum antigen (NcMIC1-3-R) [18], showed that the protection achieved with the 421 
polyvalent O-Ags formulation employed here was clearly antigen-dependent.  422 
OprI-PDI elicited the strongest humoral immune response. PDI-specific IgG levels were 423 
elevated already prior to challenge, before and after mating. However, further investigation of 424 
anti-PDI antibody levels at 9dpi in pregnant mice then demonstrated a decrease (or a lack of 425 
boost) of antibody levels. This was observed in experiments 1 and 2, but mice could be 426 
individually tracked only in experiment 2. In contrast, sera of only few mice had detectable 427 
antibodies directed against ROP2 and ROP40 when assessed by ELISA prior to challenge and 428 
this low response was confirmed by Western blotting using sera from experiment 1. Nevertheless, 429 
immunoblotting confirmed specific recNcROP2 and recNcROP40 antibody responses, since a 430 
signal against recNcROP2 was detected at 9dpi in both O-Ags and O-Ags+TLR vaccinated 431 
groups, with no signal in the C+ group. RecNcROP40 was also detected slightly by both 432 
vaccinated groups at pre-challenge phase, boosting at 9dpi in the O-Ags+TLR group.  433 
The decrease, or lack of boost, of anti-PDI antibody levels after the third immunization in 434 
the vaccinated mice was only observed in pregnant animals. This indicates immune modulation 435 
due to the pregnancy, but it is unclear how this affects the overall protectivity of the vaccine 436 
formulation. An inverse correlation between anti-PDI-antibody levels and protection against 437 
cerebral infection could be observed in dams. Those pregnant mice with a slightly increased anti-438 
PDI antibody levels between the pre-challenge and 9 dpi were those exhibiting high parasite 439 
burden and clinical signs score afterwards. Conversely, those dams showing the strongest drop of 440 
antibody levels between these two time-points were those with lowest parasite burden afterwards. 441 
However, in the pups, no correlation with vertical transmission was detected. Whether the 442 
impairment in anti-PDI antibodies boost was a consequence of an early control of parasite 443 
replication or a requisite for improved protection is not clear. A study on N. caninum profilin 444 
vaccinated mice [32] also reported on a drop of profilin-specific antibody titers shortly after 445 
challenge, and levels recovered at 21dpi.  It was suggested that antibodies were being consumed 446 
by playing an active role against the infection [35]. However, only non-pregnant animals were 447 
assessed, and in our study non-pregnant mice actually showed a strong boost of antibody levels 448 
between pre-challenge and 9 dpi, and we did not note a correlation between antibody levels at 449 
9dpi and cerebral parasite burden. Thus, the differential antibody kinetics observed here is likely 450 
to be a consequence of a pregnancy-associated phenomenon. Antibody levels are also altered 451 
during the course of N. caninum infection in cattle. In naturally infected heifers, antibody 452 
fluctuations occurring between 90 and 240 days of gestation were shown to be associated with a 453 
higher probability of vertical transmission [36, 37]. Cows that aborted also showed more 454 
pronounced fluctuations and overall higher antibody levels, especially between months 3 and 8 of 455 
gestation, compared to non-aborting cows [38]. Whether the vaccine-associated drop in antibody 456 
levels in dams compared to non-pregnant mice reflects a downregulation of total blood 457 
immunoglobulins during pregnancy needs to be further investigated. In humans, an overall 458 
reduction of total IgG and IgM was observed in healthy pregnant women compared to healthy 459 
non-pregnant women [39]. 460 
In experiment 2, cytokine levels were studied at 9dpi in peripheral blood samples, and at 461 
30dpi for non-pregnant mice and 43dpi for dams by analyzing splenocyte recall responses after 462 
stimulation with crude N. caninum extracts. Moreover, all mice were individually tracked. At 463 
9dpi, IFNγ blood levels were lower in O-Ags vaccinated mice compared to the C+ group, in both 464 
pregnant and non-pregnant mice. However, at chronic phase, namely at 43dpi, when IFNγ levels 465 
were measured in culture supernatants of stimulated splenocytes, this effect was not observed. 466 
Splenocytes from vaccinated dams with lower vertical transmission rates tended to produce more 467 
IFNγ, thus the correlation between IFNγ levels and vertical transmission was inverted. When 468 
splenocytes from non-pregnant mice were stimulated and supernatants assessed for IFNγ, higher 469 
levels were recorded in the O-Ags vaccinated group compared to C+ group. It was shown earlier 470 
that in N. caninum infected mice IFNγ levels reach a peak around 10dpi [40], which is in 471 
accordance with the highest IFNγ levels observed in our C+ group at 9 dpi. We suggest that the 472 
down-regulation of IFNγ levels at 9dpi in O-Ags mice may have contributed to the reduction of 473 
cerebral infection in non-pregnant mice and of vertical transmission in dams. A similar 474 
interesting pattern of IFNγ responses was already described [41]. Dams primo-infected during 475 
pregnancy (corresponding to our C+ group) showed increased production of IFNγ compared to 476 
non-pregnant mice peaking at 11dpi. However, those dams which were protected against vertical 477 
transmission by being infected before breeding showed a decreasing kinetic of IFNγ levels along 478 
the pregnancy and increasing at delivery [41]. Further investigations should be carried out to 479 
elucidate the role of IFNγ induced by protective vaccine formulations and how this IFNγ 480 
response is affected during pregnancy. 481 
In summary, these vaccination studies in a neosporosis mouse model have shown that 482 
promising efficacy against congenital and cerebral neosporosis can be achieved by immunization 483 
with a polyvalent combination vaccine composed of recombinant NcPDI, NcROP2 and 484 
NcROP40, all three fused to the TLR2-ligand OprI. This vaccine induced a balanced Th1/Th2 485 
immune response in adults, which reduced vertical transmission, but was not highly efficacious in 486 
preventing cerebral infection in dams. To the best of our knowledge, this is a major advance in 487 
terms of efficacy achieved with a recombinant vaccine formulation. Further studies should aim to 488 
optimize the dosage and the timing of immunizations, and it will be highly interesting to 489 
elucidate the immunological mechanisms that are responsible for the protective effects against 490 
vertical transmission.  491 
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 630 
Figure Legends 631 
Fig. 1. Schematic presentation of experiments 1 and 2. Female mice were immunized in two-632 
week intervals, twice prior to mating (Imm. I; Imm. II), and a third time (Imm. III) shortly after 633 
mating. All mice were challenged by subcutaneous inoculation of 10
5
 N. caninum tachyzoites. 634 
Mice were closely monitored for clinical signs and mortality. Non-pregnant mice were 635 
euthanized on day 30 post-infection, dams and pups were euthanized on days 43-45 post-636 
infection. Immunoglobulins (Igs) and/or cytokine responses were analyzed at different time-637 
points for experiment 1 and 2: PrCh-1= Pre-challenge time-point experiment 1 (only Igs 638 
analyzed); PrCh-2 = Pre-challenge time-point experiment 2 (only Igs analyzed); PstCh-pm = 639 
Post-challenge “post-mating” time-point (Igs analyzed for experiment 1, both Igs and cytokines 640 
for experiment 2); PstCh-NonPreg = Post-challenge “non-pregnant mice” time-point (Igs 641 
analyzed for experiment 1, both Igs and cytokines for experiment 2); PstCh-D = Post-challenge 642 
“dams” time-point (Igs analyzed for experiment 1, both Igs and cytokines for experiment 2).W = 643 
time-point of oestrus synchronization (Whitten effect); M = mating  644 
 645 
Fig. 2. SDS-PAGE and dendritic cell stimulation assays. (A) SDS-PAGE and Comassie staining 646 
of OprI-PDI, OprI-ROP2, OprI-ROP40 and OprI-OVA, all expressed in E. coli and purified as 647 
described in materials and methods. For each protein, 3, 1 and 0.3 µg (from left to right) was 648 
loaded. M = molecular weight marker. (B) TNF-alpha levels in medium supernatants following 649 
stimulation of mouse bone marrow-derived dendritic cells with 1 or 5 µg of OprI-PDI, OprI-650 
ROP2 or OprI-ROP40, compared with TNF-alpha-levels in supernatants of DC cultures 651 
stimulated with the corrersponding non-OprI-antigens. Each assay was done in triplicates, and the 652 
error bar indicates the standard error of the mean (SEM). 653 
 654 
Fig. 3. Kaplan Meier survival curves of pups from experiment 1 (A) and experiment 2 (B). 655 
 656 
Fig. 4. Cerebral parasite burden measured by real-time PCR in dams from experiment 1 (A) and 657 
2 (B) at 40-44 dpi, and from non-pregnant mice from experiment 2 at 30 dpi (C). Experiment 1 is 658 
not shown since only one mouse from the O-Ags group remained non-pregnant. (D) shows the 659 
clinical signs score of non-pregnant mice in experiment 2. 660 
 661 
Fig. 5. Humoral immune responses against recombinant antigens. A) Western blot analysis of 662 
pooled sera obtained from experiment 1. Recombinant ROP2 (rROP2) (MW = 41 kDa) and 663 
rROP40 (MW = 49 kDa) were separated by SDS-PAGE, blotted onto nitrocellulose, and rROP2- 664 
and rROP40-specific IgG were detected by immunoblotting in mouse sera obtained at the pre-665 
challenge phase prior to mating (PrCh-1) and at 9 dpi coinciding with days 14-16 of pregnancy 666 
(PstCh-pm.). “+” depicts a positive control serum from a mouse that was chronically infected 667 
with N. caninum. 1, 2, and 3 strips represent dilutions 1:50, 1:200 and 1:800 of pooled sera. 668 
Arrowheads indicate the location of recombinant proteins. (B) ELISA-based detection and 669 
quantification of PDI-specific IgG1 and IgG2a levels in experiment 1. PDI-specific antibodies in 670 
mice vaccinated with O-Ags and O-Ags+TLR ligands collected at the pre-challenge phase prior 671 
to mating (PrCh-1) and at 9 dpi coinciding with days 14-16 post mating (PstCh-pm). (C) Ratio of 672 
IgG1:IgG2a. Dots represent individual values of 4 randomly chosen mice euthanized at PrCh-1 673 
and 3 pregnant mice randomly chosen to be euthanized at PstCh-pm. Horizontal lanes represent 674 
the median in each group. 675 
 676 
Fig. 6. IgG1 and IgG2a antibodies against soluble N. caninum extract in sera from mice from 677 
experiment 2. Sera were from vaccinated groups (O-Ags, O-Ags+TLR, O-Ova) and the non-678 
vaccinated and infected group (C+) collected at the end of the experiment (30 dpi for non-679 
pregnant mice and 40 dpi for dams). (*) indicates statistically significant differences (Mann-680 
Whitney U test, P<0.05). 681 
 682 
Fig. 7. Cytokine levels measured in blood samples obtained at 9 dpi coinciding with days 14-16 683 
post-mating (PstCh-pm.) in experiment 2. Boxes represent median, 25
th
 and 75
th
 percentiles; 684 
whiskers and individual points represent extreme values by Tukey method. (*) indicates 685 
statistically significant differences, Kruskal-Wallis, P <0.05.  686 
 687 
Fig. 8. Cytokine responses after splenocyte restimulation in vitro with N. caninum crude extract 688 
in dams (40 dpi) and non-pregnant (30 dpi) mice at the end of experiment 2. Boxes represent 689 
median, 25
th
 and 75
th
 percentiles; whiskers and individual points represent extreme values by 690 
Tukey method. (*) and (**) show Kruskal-Wallis, P < 0.05 and P < 0.01 statistically significant 691 
differences, respectively, compared to C- group. 692 
 693 
  694 
 695 
Table 1. Outcome of Neospora caninum infection in dams and pups in experiments 1 and 2. 696 
Group Experiment Fertilitya 
No. 
damsb 
Litter 
sizec 
Neonatal 
mortalityd 
Postnatal 
mortalitye 
Postnatal 
survivalf 
Median 
survival 
timeg 
Vertical 
transmissionh 
O-Ags Exp. 1 
14/15 
(93.3%)  
11 5.2 
8/57 
(14.0%) 
32/49 
(65.3%) 
17/49 
(34.7%) 
18 
39/49 
(79.6%) 
O-Ags Exp 2. 
9/20 
(45%) 
9 6.6 
5/59 
(8.5%) 
31/54 
(57.4%) 
23/54 
(42.6%) 
21.5 
35/54 
(64.8%) 
O-
Ags+TLR 
Exp. 1 
9/16 
(56.3%) 
6 5.7 
3/34 
(8.8%) 
26/31 
(83.9%) 
5/31 
(16.1%) 
16 
28/31 
(90.3%) 
O-OVA Exp. 2 
9/20 
(45%) 
9 6.3 
3/57 
(5.3%) 
47/54 
(87.0%) 
7/54 
(12.9%) 
16.5 
48/54 
(88.9%) 
C+ Exp. 1 
11/20 
(55%) 
8 5.6 
14/45 
(31.1%) 
28/31 
(90.3%) 
3/31 
(9.7%) 
15 
30/31 
(96.8%) 
C+ Exp. 2 
14/20 
(70%) 
14 6.4 
6/89 
(6.7%) 
70/83 
(84.3%) 
13/83 
(15.7%) 
16 74/83 (89.2) 
C- Exp. 1 
11/16 
(68.8%) 
8 5.9 
14/47 
(29.8%) 
0/33  
(0%) 
33/33 
(100%) 
Undef. 0/33 (0%) 
C- Exp. 2 
10/20 
(50%) 
10 6.2 
2/62 
(3.2%) 
0/60  
(0%) 
60/60 
(100%) 
Undef. 0/60 (0%) 
a
 Proportion of pregnant mice per group (%) 697 
b
 In experiment 1, three pregnant mice were excluded because they were euthanized before birth for blood 698 
sampling. 699 
c
 Number of delivered pups per dam 700 
d
 Proportion of pups born dead or that died within the first 2 days post-partum (%) 701 
e
 Proportion of pups died from day 3 to 30 post-partum (%) 702 
f
 Proportion of survival pups at day 30 post-partum (%) 703 
g
 Day post-partum at which 50% of pups were dead 704 
h
 Proportion of Neospora caninum-PCR positive surviving pups plus those which died from day 3 post-partum 705 
(dead pups from day 3 post-partum are considered N. caninum-PCR positive as previously shown (Dellarupe et 706 
al., 2014)). 707 
Undef.: undefined, no pup mortality.  708 
 709 
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Abstract 25 
 26 
OprI is an outer membrane lipoprotein from Pseudomonas aeruginosa, and when fused to a 27 
recombinant antigen, will exert adjuvant properties by engaging Toll-like receptor 2, leading to 28 
dendritic cell activation. Previous studies have shown that the Neospora caninum (Nc) antigens 29 
NcPDI, NcROP2 and NcROP40 are implicated in host cell interactions and are promising 30 
vaccine candidates. In two independent experiments, the efficacy of a polyvalent vaccine 31 
formulation composed of OprI-NcPDI, OprI-NcROP2 and OprI-NcROP40 (collectively named 32 
O-Ags) was assessed in non-pregnant and pregnant Balb/c mouse models challenged with 33 
tachyzoites of the high-virulence isolate Nc-Spain7. Parameters that were investigated were 34 
clinical signs, fertility, efficacyparasite burden in adult mice, humoral and cellular immune 35 
responses at different time-points prior to and after challenge infection, vertical transmission and 36 
post-natal survival of offspring mice, all to explore potential correlations with efficacy. 37 
Vaccination of mice with O-Ags induced a mixed Th1/Th2 immune response in adult mice and 38 
led to significantly increased protection against cerebral infection. Vaccination with O-Ags also 39 
resulted in reduced vertical transmission, and postnatal disease in offspring was significantly 40 
inhibited at a rate not observed in mice infected with a high-virulence isolate to date. However, 41 
O-Ags mixed with TLR ligands targeting TLR3 and TLR7, which are known to induce clear 42 
Th1-biased responses, or vaccination with OprI fused to the non-N. caninum antigen ovalbumin 43 
(OprI-OVA) did not confer protection. 44 
 45 
 46 
Keywords: Neosporosis; mouse model; pregnancy; vaccine; dendritic cells; immunomodulation; 47 
rhoptries; protein disulfide isomerase  48 
 49 
1. Introduction 50 
Neospora caninum is a cyst-forming coccidian closely related to Toxoplasma gondii, and is 51 
one of major causes of infective abortion in cattle [1]. In addition, N. caninum infection in cattle 52 
often results in birth of weak calves or persistently infected offspring, which then transmits the 53 
parasite to the next generation. Vaccination has been considered to be the most cost-effective 54 
strategy to control bovine neosporosis [2,3], but no commercial vaccines are available [4]. 55 
Live vaccines based on attenuated N. caninum isolates partially protected mice and cattle 56 
against fetal death upon experimental challenge infection during pregnancy [5,6,7]. However, 57 
several disadvantages of live vaccines related to costs of parasite in vitro culture, storage, limited 58 
shelf life of the final product and logistics of its distribution, as well as the potential risks of 59 
virulence reversion and recombination between attenuated and circulating strains, render live 60 
vaccines a rather unattractive option [4]. Vaccines based on total antigenic extracts or different 61 
antigenic fractions of the parasite have shown variable results with overall lower success [7]. 62 
Subunit vaccines composed of recombinant antigens would represent an interesting option and 63 
would solve many of the inherent logistic and financial disadvantages of live vaccines [4]. 64 
Admittedly, recombinant vaccine formulations have so far not shown very promising effects in 65 
pregnant neosporosis animal models. However, the versatile potential of recombinant vaccines 66 
should be much more exhaustively exploited by applying antigen combinations with adjuvants 67 
targeting different components of the immune system [4].  68 
There is “proof-of-concept” that a reduction of vertical transmission and postnatal 69 
mortality due to N. caninum infection can be achieved by vaccination not only with live vaccines 70 
[8,9], but also with recombinant subunit vaccines in mice [10,11]. Bacterially expressed 71 
recNcPDI, recNcROP2 and recNcROP40 represent promising vaccine candidates. Immunization 72 
of mice with recNcROP2 formulated in saponin resulted in a significantly increased survival rate 73 
in adult mice [12] and in offspring born to mice infected during pregnancy with the N. caninum 74 
Nc-1 isolate [10]. NcROP40 is another rhoptry protein that is abundantly expressed in virulent N. 75 
caninum isolates [13]. Immunization of mice with both recNcROP40 and recNcROP2 76 
recombinant proteins lead to reduction of vertical transmission and postnatal mortality of 16% in 77 
offspring born to mice infected with the highly virulent isolate Nc-Spain7 [11]. RecNcPDI (N. 78 
caninum protein disulfide isomerase) had conferred protection against cerebral neosporosis when 79 
applied intranasally [14], but failed to protect dams and their offspring [2].  80 
The TLR2-ligand OprI is an outer membrane lipoprotein from Pseudomonas aeruginosa 81 
[15].. It has been used to confer adjuvant properties when expressed in fusion with different 82 
antigens.  [15]. Different immune functions have been attributed to TLR2 signaling including the 83 
promotion of a mixed and balanced Th1-, Th2- and Th2-Treg cell response [16] and a T-cell 84 
tropism to mucosal tissues even when inoculated via a non-mucosal route [17]. In previous 85 
immunization studies, OprI had been fused to the N. caninum chimeric antigen Mic3-1-R, and 86 
vaccinated mice were challenged during pregnancy. This did not result in protection, neither in 87 
dams nor in offspring mice, but we nevertheless detected that fusion of OprI to MIC3-1-R 88 
induced a mixed Th1/Th2 profile response [18], while the immune response in mice immunized 89 
with MIC3-1-R emulsified in saponin was  largely Th2-biased, thus confirming the 90 
immunomodulatory properties of OprI-fusions. This well-adjusted Th1/Th2 balance is required to 91 
protect N. caninum vaccinated mice during pregnancy when a strong Th1 response could be 92 
detrimental [30].   93 
In this study, we performed two independent experiments to assess the efficacy of a 94 
polyvalent vaccine formulation composed of OprI-NcPDI, OprI-NcROP2 and OprI-NcROP40 95 
(collectively named O-Ags) in non-pregnant and pregnant Balb/c mouse models challenged with 96 
N. caninum tachyzoites. In one of the experiments, the same O-Ags formulation was mixed with 97 
two additional TLR ligands targeting TLR3 and TLR7, which are known to induce clear Th1-98 
biased responses [19] and likewise effects in dams and offspring were assessed. In the other 99 
experiment, a group vaccinated with OprI fused to ovalbumin (OprI-OVA) was included to 100 
provide an irrelevant antigen control.  101 
 102 
2. Materials and methods 103 
 104 
2.1. Neospora caninum culture, inoculum and crude extract preparation  105 
 106 
The N. caninum Nc-Spain7 isolate [20] was grown in vitro by continuous passages in 107 
Vero cell cultures [18]. The parasite inoculum was prepared as described [21]. N. caninum crude 108 
extract for lymphocyte re-stimulation assay and Western blot, and soluble antigen fractions for 109 
ELISA, were prepared as described earlier [18].  110 
 111 
2.2. Production of recombinant antigens fused to OprI 112 
 113 
The coding sequence of NcPDI (aa 25-446) [22], a fragment of NcROP2 (aa 238-594) 114 
[12] and the complete coding sequence of NcROP40 [11] were cloned in the pOLP plasmid in 115 
frame wiuthwith OprI [15]. A previously described plasmid, containing the ovalbumin (OVA) 116 
partial sequence (aa 203-386) in frame with OprI [16] was also used to obtain the unrelated 117 
antigen OprI-OVA. Proteins were all expressed in Rosetta(DE3)pLysS Escherichia coli strain 118 
(Novagen). They were isolated from the bacterial outer membranes as previously described [18]. 119 
Purified OprI-NcPDI was dialyzed against PBS over-night at 4°C and stored at -80°C. OprI-120 
NcROP2 and OprI-NcROP40, expressed less efficiently and insoluble in aqueous solution, were 121 
dialyzed over-night against 1g/L ammoniumbicarbonateammonium bicarbonate at 4°C and 122 
lyophilized. They were resuspended in PBS in one-tenth of the original volume, vortexed, and 123 
were sonicated at 30°C in a water bath until a homogeneous suspension was obtained. All 124 
purified OprI-antigens were finally stored at -80°C. Non-OprI-fused NcPDI, NcROP2 and 125 
NcROP40 [11,22,22], were expressed and purified as described [18]. The purity and integrity of 126 
all proteins were analyzed by SDS-PAGE and the protein concentration was determined (BCA 127 
Protein Assay Kit, Thermo Scientific Pierce). Endotoxin levels were quantified by the Limulus-128 
Amebocyte-Lysate-Kinetic-QCL (Lonza). The final LPS content was below 0.1EU/µg. 129 
 130 
2.3. Dendritic cell (DC) stimulation 131 
 132 
OprI-fused and non-fused recombinant proteins were assessed for DC stimulation [18]. 133 
Briefly, DCs were obtained in vitro from bone marrow cells obtained from a naïve Balb/c mouse. 134 
DCs (0.5x10
6 
cells/ml),) were cultured in the presence of each protein (1 or 5μg/ml), LPS 135 
(0.1μg/ml) or medium during 24hours, and TNF-α was measured in the culture supernatants by 136 
ELISA [18]. 137 
 138 
2.4. Immunization schedule, clinical monitoring and sample collection 139 
 140 
All animal protocols were approved by the Bernese Animal Welfare Committee (license 141 
BE115/14.) Two experiments were carried out. Schedules of immunization, mating, blood sample 142 
collection and euthanasia for both studies are depicted in Fig.1. Six weeks-old BALB/c mice 143 
were purchased from Charles River Laboratories (Sulzfeld, Germany) and maintained as 144 
described [18].  145 
In Experiment 1, 16 to 20 female mice per group were immunized three times, at two-146 
week intervals. The O-Ags group was subcutaneously injected with all three OprI-antigens, 5µg 147 
each; the O-Ags+TLR group was immunized with the same antigens mixed with poly I:C (TLR3 148 
ligand) (Invivogen) and R848 (TLR7 ligand) (Invivogen), 25µg each. Two control groups, one of 149 
which remained non-infected throughout the experiment (C-), the other one that was infected 150 
(C+), received PBS only. Eight days after the second injection, just prior to the oestrus 151 
synchronization, a blood sample was obtained from 4 mice per group (see Fig.1; PrCh-1) and 152 
serum recovered for IgG analysis.  153 
In experiment 2, experimental groups of 20 female mice were immunized subcutaneously 154 
three times, at two-week intervals. The O-Ags group received the three antigens as above, the O-155 
OVA group was injected with 15µg of OprI-OVA, the two additional groups (C- and C+ groups, 156 
see above) received PBS. A blood sample from the tail was obtained from all mice 34 days after 157 
the third immunization (at 4-7 days post-mating) just prior to challenge (Fig.1; PrCh-2). 158 
Eight days post- second immunization, all micemice in both experiment 1 and experiment 159 
2 were submitted to oestrus synchronization [23] and 2 females and 1 male per cage were mated 160 
during 72h. The third immunization was applied after separation of males and females, 5 days 161 
prior to challenge infection. At 5-8 days of pregnancy, mice from the O-Ags, O-Ags+TLR, O-162 
OVA and C+ groups were subcutaneously infected with 10
5
 Nc-Spain7 tachyzoites [24]. Mice of 163 
the C- groupgroups received only PBS. At day 9 post-challenge, infection, a blood sample was 164 
obtained from the tail of 3 pregnant mice of each group from experiment 1 were euthanized, and 165 
blood was collected by intracardiac puncture, whereas inof all mice from experiment 2 a blood 166 
sample was obtained from the tail of all mice (Fig.1; PstCh-pm). On day 18 post-matingTwo days 167 
before birth, pregnant and non-pregnant mice were separated. Dams were allowed to give birth 168 
and rear their offspring in individual cages. Non-pregnant mice were kept in groups of 4-5 mice 169 
per cage. Following infection, all mice were daily monitored for clinical signs using a 170 
standardized score sheet: coat (ruffled coat=score1; stary stiff coat=score2); weight loss (10% 171 
loss=score1, 15-20% loss=score 4); behavior (hunched appearance, walking in circles, head tilt, 172 
apathy and ataxia, all=score 1). Animal were euthanized when the score exceeded 3 points.   173 
At 30 days post-infection (30 dpi), all surviving non-pregnant mice in both experiments 174 
were euthanized (Fig.1; PstCh-NonPreg). Dams and their pups were maintained together until 175 
day 30 post-partum (pp) (=41-44 dpi), subsequently all animals were euthanized (Fig.1; PstCh-176 
D).  177 
Data on clinical signs, fertility (percentage of pregnant mice), litter size (average of 178 
number of pups born per dam), neonatal mortality of pups (stillborn pups or pups dying within 179 
the first 2 days post-partum (dpp) and postnatal mortality (pups dying between day 3 and 30pp) 180 
were recorded. Upon euthanasia, blood was extracted by cardiac puncture and sera stored at -80 181 
°C. Brains from non-pregnant mice, dams and surviving pups were also collected and 182 
immediately frozen at -20°C. Spleens from 5 to 6 non-pregnant mice and dams per group were 183 
aseptically recovered and processed for splenocyte re-stimulation in vitro. 184 
 185 
2.5.Analysis of the cerebral parasite burden 186 
 187 
Brains from non-pregnant mice, dams and surviving pups were analyzed by N. caninum-188 
specific real-time PCR [25]. DNA extraction was performed using the Nucleospin Kit 189 
(Macherey-Nagel, Oensingen, Switzerland). The DNA concentration in all samples was 190 
determined using the QuantiFluor dsDNA System (Promega, Madison, Wi.) and was adjusted to 191 
5ng/µl with sterile DNase free water. Quantitative real-time PCR was performed using the Rotor-192 
Gene 6000 real-time PCR machine. The parasite load was calculated by interpolation from a 193 
standard curve with DNA equivalents from 1000, 100 and 10 N. caninum tachyzoites included in 194 
each run. 195 
 196 
2.6. Assessment of cytokine expression levels in serum and splenic lymphocytes stimulated in 197 
vitro 198 
 199 
Levels of mouse IFN-γ, IL-10, IL-2 and IL-5 were assessed at two different time-points in 200 
experiment 2: (i) at 9dpi, coinciding with days 14-1617 of pregnancy (PstCh-pm, see Fig.1) in 201 
blood, and (ii) at the late post-challenge phase in non-pregnant mice (30 dpi) and dams (43-45 202 
dpi) by splenocyte re-stimulation in vitro as described [18]. For cytokine assessment in blood, the 203 
serum samples were analysed by bead-based multiplex assay for the Luminex® platform 204 
(Hertogenbosch, The Netherlands) . Microtiter filter plates were run on Luminex instruments 205 
(Bio-Plex
TM
200 system). Calibration curves were calculated with Bio-Plex Manager software 206 
using a five-parametric logistic curve fitting [18]. For cytokine analysis upon splenocyte recall 207 
responses, spleens were disaggregated and splenocyte cell suspensions were prepared as 208 
described [18], The resulting cell suspensions were seeded in 48-well plates and re-stimulated 209 
with either concanavalin A (ConA; 5µg/ml; Sigma), recNc-PDI, NcROP2, NcROP40 (20µg/ml), 210 
whole N. caninum crude extract (10µg/ml) or remained non-stimulated. Supernatants were 211 
collected after 72h and stored at -80°C until cytokines were assessed by ELISA (BD 212 
OptEIA™ Mouse ELISA Set, LifeSpan Biosciences Inc., Seattle, WA, USA).  213 
  214 
2.7. Analysis of serum immunoglobulins  215 
 216 
Immunoglobulins were analyzed at different time-points: (i) during the pre-challenge 217 
phase prior to mating in experiment 1 (PrCh-1); (ii) during pre-challenge phase after mating in 218 
experiment 2 (PrCh-2); (iii) during the early post-challenge phase in experiments 1 and 2 (PstCh-219 
pm); (iv) at the late post-challenge phase just prior to euthanasia in non-pregnant mice (PstCh-220 
NonPreg) and in dams (PstCh-D) (see Fig.1). Serum levels of N. caninum, NcPDI-, NcROP2- or 221 
NcROP40-specific IgG1 and IgG2a were measured by ELISA [26]. Four 4-fold serial dilutions 222 
were analyzed for each sample and results were expressed as end-point titer (EPT) calculated as 223 
the inverse value of the dilution giving an OD≥cut-off [27]. The cut-off was independently 224 
positioned in each plate in the lower linear part of the dilution curve of the same positive control 225 
which allowed the normalization between plates. 226 
PrCh-1 and PstCh-pm serum samples from experiment 1 were also analyzed in pools by 227 
immunoblotting for NcROP2- and NcROP40-specific IgG. Non-OprI- NcROP2 and NcROP40 228 
(10µg each) were submitted to Western blot analysis following standard procedures [26]. Pooled 229 
sera were incubated at 1:50, 1:200 and 1:800 dilutions and an anti-mouse IgG antibody 230 
conjugated to alkaline phosphatase (eBioscience) at 1:5000 dilution was employed. 231 
 232 
2.8.Statistical analysis 233 
Cytokines levels, clinical signs scores and cerebral parasite burdens were compared 234 
between groups by the non-parametric Kruskal-Wallis test; upon detection of statistical 235 
differences, a Dunn’s multiple comparison test was subsequently applied to compare pair-by-pair. 236 
End point titer (EPT)titers of IgG1 and IgG2a or ratios IgG1:IgG2a were compared between 237 
groups by Kruskal-Wallis test followed by Dunn’s multiple comparison post-test or by U Mann-238 
Whitney U test when only two groups were compared at pre-challenge and pregnancy phases or 239 
between dams and non-pregnant mice in each group. Repeated measures of PDI antibodies along 240 
time were compared by Wilcoxon matched pairs test. Correlations between parasite burden or 241 
vertical transmission and any immune parameters were analyzed by Pearson correlation 242 
coefficient. To compare the mortality of pups along time, survival proportions at each time-point 243 
were plotted in Kaplan-Meier graphs and survival curves were compared by Log-rank test. The 244 
percentages of survivors at the end of the experiment or percentages of N. caninum PCR positive 245 
samples were analyzed by Chi-square test with Yates’ continuity correction in a contingency 246 
table.  247 
Regarding the parameters measured in both experiments and compared between groups 248 
(C-, O-Ags and C+), a unique statistical analysis was done with all data from both experiments. 249 
A mixed-effects log-linear model (Venables and Ripley, 2002) was used to analyze pregnancy 250 
and immunization with the O-Ags formulation as fixed effects on parasite burden, having 251 
experiment as random effect. Effect sizes were estimated with a penalized quasi-likelihood 252 
method (glmmPQL from MASS library). A logistic mixed model with Laplace parameter 253 
estimation via Lapplace approximation (glmer of lme4 package) was used to evaluate clinical 254 
signs presence and vertical transmission. The odds-ratio (OR) relative to the O-Ags group was 255 
calculated. with the respective 95% confidence interval (CI 95%). Survival of pups was 256 
compared with a Cox model with fixed (immunization) and random (experiment) effects (coxme 257 
library). Statistical significance was established at P<0.05. 258 
 259 
3. Results  260 
 261 
3.1. Increased dendritic cell stimulation by OprI-fused recombinant antigens 262 
 263 
The purified OprI-fused recombinant proteins shown in Fig.2A were used for stimulation 264 
of bone marrow-derived DCs, which  were cultured in the presence of 1 or 5 µg/ml of each 265 
protein, LPS (0.1μg/ml) or medium during 24 hours, and the production of TNF-α was measured 266 
in the culture supernatants by ELISA (Fig.2B). In contrast to the non-fused recombinant antigens, 267 
the OprI-proteins induced strong and specific DC stimulation (Fig.2B). 268 
 269 
3.2. Immunization with OprI-fused Neospora antigens reduced vertical transmission and 270 
increased postnatal survival  271 
 272 
Table 1 shows the outcome of N. caninum infection in dams and pups in both 273 
experiments. Comparing the O-Ags groups and the C+ infection control groups in both 274 
experiments, using the experiment as random effect in the mixed model, there was a significant 275 
differenceincrease in survival of offspring of immunized animals (O-Ags groups P <0.001) and a 276 
significant reduction in vertical transmission (OR=4.52, CI 95% [2.06;10.63],  P<0.001).  277 
Analyzing experiment 1 separately, offspring from O-Ags group also showed a significant 278 
higher survival compared to C+ (χ
2
 and Log-rank test, P <0.05). In the O-Ags+TLR group in 279 
experiment 1 (Fig.3A), the pup survival curves werecurve was also significantly different from 280 
the O-Ags group (Log-rank test, P<0.01), showing that supplementation of the O-Ags 281 
formulation by TLR3 plus TLR7 ligands abolished the protective effect of O-Ags immunization.  282 
In fact, the O-Ags+TLR group the pup survival curveof pups was not significantly different from 283 
C+ (O-Ags+TLR vs C+; χ
2
 and Log-rank test, P >0.05) (Table 1; Fig. 3A). 284 
In experiment 2 (Fig. 3B), comparing the C+ group with the O-Ags group, the 285 
puppercentage of pups survival and the pup survival curves from O-Ags were also significantly 286 
different (higher (χ
2
 and Log-rank test, P <0.01).) and the vertical transmission significantly 287 
lower than C+ (χ
2
 and Log-rank test, P <0.01). Here, a group of mice was immunized with OprI 288 
fused to ovalbumin (O-OVA group). In thethis latter group immunized with O-OVA, the 289 
percentage of surviving pups, the pup survival curve wasand the vertical transmission were 290 
identical to C+ (O-OVA vs C+; χ
2
 and Log-rank test, P >0.05) (Table 1; Fig.3B). 291 
 292 
3.3. Immunization with OprI-fused Neospora antigens reduced cerebral neosporosis  293 
Taking into account both experiments in the mixed-effects log-linearlogistic model there 294 
was a significant effect of O-Ags vaccination on the likelihood of animals developing clinical 295 
signs, with C+ animals at higher risk (OR=12.6, CI 95% [1.76; 260.66],  P<0.05) independent of 296 
pregnancy. A significant effect of both O-Ags immunization (P<0.001) and pregnancy (P<0.01) 297 
on the cerebral parasite burden, without a significant interaction between these two variables, 298 
(P>0.05), was observed with the mixed effects log linear model (Fig.4A,B)).  Compared to non-299 
immunized mice, (C+), O-Ags vaccinated dams showed lower parasite burdens (Fig.4A,B). In.  300 
In experiment 1 and 2, dams immunized with O-Ags+TLR or O-OVA, no reduction in  301 
did not show reduced cerebral parasite burden was detectedcompared to C+ (Kruskal-Wallis, 302 
P>0.05) (Fig.4A,B). ImmunizationRegarding non-pregnant mice, immunization with O-Ags also 303 
impacted on reduced significantly the cerebral parasite burden and clinical signs in non-pregnant 304 
immunized animals (Fig.4C,D). This could only be seen in experiment 2 (O-Ags vs C+; Kruskal-305 
Wallis, P <0.05), since in experiment 1 only one mouse from O-Ags was not pregnant. No 306 
protective effect was observed in the one non-pregnant mouse mice immunized with O-Ags+TLR 307 
(data not shown) or in the O-OVA immunized mice (Kruskal-Wallis, P>0.05) (Fig.4C). 308 
 309 
3.4. Humoral immune responses against recombinant antigens  310 
 311 
Specific antibody responses against each of the recombinant antigens used for 312 
immunization were studied by ELISA in both experiments at different time-points in the pre-313 
challenge phase, either prior to mating in experiment 1 (PrCh-1) or 5 days post-mating in 314 
experiment 2 (PrCh-2), and at 9dpi (14-16 days post-mating; PstCh-pm.). Specific anti-ROP2 and 315 
anti-ROP40 antibody levels were very low at both pre-challenge time-points and several animals 316 
remained ELISA-seronegative when assessed even at 9dpi) in both experiments. Thus, pools of 317 
sera collected at the pre- and post-challenge time-points in experiment 1 were analyzed by 318 
Western blotting (Fig.5A). Anti-ROP2 antibodies remained virtually undetectable in sera taken 319 
during the pre-challenge phase in the groups immunized with O-Ags and O-Ags+TLR, but. 320 
However,  IgG levels in O-Ags and O-Ags+TLR were higher in sera taken during pregnancy at 9 321 
dpi, (PstCh-pm), especially in the group immunized with O-Ags. Anti-ROP40 IgG levels were 322 
also low in both groups prior to challenge but were dramatically elevated in the group immunized 323 
with O-Ags+TLR in post-challenge sera taken from pregnant mice (PstCh-pm) (Fig.5A). Sera 324 
obtained from the O-OVA and the C+ group remained negative for ROP2 and ROP40 at both 325 
PrCh-1 and PstCh-pm. 326 
PDI-specific antibodies were detected by ELISA during the pre-challenge phase. In 327 
experiment 1, levels in mice vaccinated with O-Ags+TLR were higher than those in mice 328 
vaccinated with O-Ags, and in spite of the low number of samples the difference reached 329 
statistical significance for IgG2a at the pre-challenge phase in experiment 1 (PrCh-1; 330 
UMannMann-Whitney U test, P<0.05) (Fig.5B). Moreover, the IgG1:IgG2a ratio was markedly 331 
lower in the O-Ags+TLR group compared to the O-Ags group, and was statistically significant 332 
during the pre-challenge phase (U Mann-Whitney U test, P< 0.05) (Fig.5B5C). Surprisingly, PDI 333 
antibody levels were lower at 9dpi (PstCh-pm) than before mating in both vaccinated groups 334 
(Fig.5B). Since the values at 9dpi corresponded to just three pregnant animals and no 335 
identification of mice was carried out, we could not deduce the individual evolution of antibody 336 
levels in experiment 1. Thus, in experiment 2 mice were individually tracked. With the exception 337 
of one, those O-Ags-vaccinated mice with confirmed pregnancy exhibited very little changes or 338 
decreased anti-PDI antibody levels during the timespan between pre-challenge to 9dpi (Wilcoxon 339 
matched pairs test; P>0.05), whereas those mice that did not become pregnant exhibited a clear 340 
boost of anti-PDI antibody levels (Wilcoxon matched pairs test, P<0.01) (suppl. Fig.1), 341 
confirming the results from experiment 1. The same tendency was observed with IgG2a levels 342 
(data not shown). Only one pregnant mouse exhibited a strong increase of antibody levels, and 343 
this animal had a very high parasite burden, elevated clinical signs score, and vertical 344 
transmission of N. caninum tachyzoites to its offspring (suppl Fig.1).  345 
 346 
3.5.Antibody responses against soluble N. caninum antigens  347 
 348 
No significant differences in IgG1 or IgG2a levels between groups were detected (two-way 349 
ANOVAKruskal-Wallis, P>0.05) (Fig.6). In sera from mice immunized with O-Ags, and O-350 
OVA, and from infected non-immunized C+ mice, similar IgG2a levels were noted in dams and 351 
non-pregnant mice (U mannMann-Whitney U test, P>0.05), whereas IgG1 levels were 352 
significantly lower in non-pregnant mice compared to dams (UmannMann-Whitney U test, 353 
P<0.05) pointing towards an IgG2a-biased response in non-pregnant mice compared to dams. In 354 
contrast, in sera of mice vaccinated with O-Ags+TLR ligands, no such differences between dams 355 
and non-pregnant were detected (UmannMann-Whitney U test, P>0.05), and the humoral 356 
immune response was IgG2a-biased in both cases. (Fig. 6). 357 
  358 
3.6.Cytokine responses  359 
 360 
Cytokines were measured in experiment 2 at 9dpi in peripheral blood and at the end of the 361 
experiment upon in vitro stimulation of splenocytes and analysis of culture supernatants. At 9dpi, 362 
the levels of IFNγ, IL-10 and IL-5 in peripheral blood were significantly elevated in all infected 363 
animals when compared to group C- (Fig.7). However, IFNγ-levels in pregnant as well as non-364 
pregnant mice vaccinated with O-Ags were significantly lower than in the C+ group (Kruskal-365 
Wallis, P<0.05). IL-10 levels were also significantly lower in non-pregnant mice vaccinated with 366 
O-Ags compared to non-pregnant mice in the C+ group. No significant levels of IL-2 were 367 
detected in peripheral blood samples of any group. (data not shown). 368 
At the end of the experiment mice were sacrificed, splenocytes were cultured and cytokine 369 
recall responses were measured in medium supernatants. In non-pregnant mice, only splenocytes 370 
from O-Ags and O-OVA vaccinated mice displayed a consistent increase of IFNγ and IL-10 371 
secretion upon stimulation with N. caninum crude extract, compared to splenocytes from C- mice 372 
(Kruskal-Wallis, P<0.05) (Fig.8). Splenocytes derived from the C+ group showed no changes or 373 
very little increase of cytokine production. In the case of vaccinated dams, splenocyte cytokine 374 
levels were more heterogeneously distributed, with high individual variations, with the exception 375 
of highly elevated IL-2 responses in splenocytes isolated from O-Ags vaccinated dams, (Fig.8).  376 
 377 
 378 
4. Discussion 379 
 380 
The development of sub-unit vaccines against parasitic diseases is a major challenge due 381 
to the complexity of the biology of parasites [28]. This is especially true in the case of congenital 382 
neosporosis, for which so far only live-attenuated vaccines have achieved reasonable levels of 383 
protection against vertical transmission [29, 0]. In the present work, an immunogenic formulation 384 
composed of three recombinant N. caninum antigens fused to OprI was assessed in a standardized 385 
pregnant mouse model of neosporosis based on the highly virulent N. caninum isolate Nc-Spain7. 386 
The vaccine formulation was composed of bacterially expressed and purified recNcPDI, NcROP2 387 
and NcROP40, all three N-terminally fused to the OprI lipoprotein., a tri-acylated bacterial outer 388 
membrane protein.  OprI targets TLR2, and thus stimulates mixed Th1, Th2 and Treg responses, 389 
favoring cross-presentation by APCs [16] Moreover, OprI was able to modulate the cellular 390 
immune response against N. caninum towards a mixed Th1/Th2 response in mice vaccinated with 391 
the N. caninum chimeric antigen Mic3-1-R [18]. The NcROP40 gene was found to be identical in 392 
three N. caninum isolates displaying different virulence, which renders this a promising vaccine 393 
candidate [31,32]. RecNcROP2 had been demonstrated to confer significant protection in non-394 
pregnant and pregnant neosporosis mouse models based on the  N. caninum Nc1 isolate [10,12]. 395 
RecNcPDI had conferred excellent protection in non-pregnant mice when applied intranasally 396 
emulsified in cholera toxin, but failed to prevent congenital neosporosis in pregnant mice [2, 14]. 397 
Nevertheless, since TLR2-ligands have shown to induce mucosal immunity by imprinting 398 
lymphocyte tropism to mucosae, even though they are applied by non-mucosal route [17], and 399 
NcPDI had conferred mucosal immunity [14], we incorporated this protein into the polyvalent O-400 
Ags formulation. 401 
We show here in two independent experiments that immunization with O-Ags confers 402 
significant protection in offspring born to dams that were challenged with N. caninum tachyzoite 403 
infection on day 7-9 of pregnancy. Postnatal mortality was reduced by 25.0 and 26.9% of pups in 404 
experiment 1 and 2, respectively, the mean survival time was extended and, overall, there was a 405 
clear difference in the survival curves.  This rate of protection against congenital neosporosis has 406 
not been seen with recombinant antigens before (11). Vertical transmission (including dead pups 407 
and PCR positive survivors) was reduced in 17.2 and 24.4% of pups, respectively, showing a 408 
significant effect of immunization. In addition, vaccinated dams and non-pregnant mice exhibited 409 
significantly less parasite burden, compared to the corresponding control groups, and the 410 
likelihood of developing clinical signs was strongly reduced, with non-vaccinated animals at 411 
higher risk. 412 
In contrast to vaccination protocols applied earlier [2,10,11], the third immunization was 413 
applied just after males and females were separated, 5 days prior to challenge infection. This 414 
immunization protocol was safe and did not impair pregnancy. Applying the final immunization 415 
during, rather than prior to, pregnancy could favor an immune response that is adequate for 416 
pregnancy maintenance without losing efficacy against N. caninum infection, as shown for 417 
several human vaccines [33].  418 
The protection induced by immunization of mice with O-Ags was abrogated by adding 419 
the TLR-3 ligand Poly I:C and the TLR7-ligand R848 as additional adjuvants. Thus, the 420 
protection observed was associated with the particular OprI-adjuvant effect. TLR3 and TLR7 are 421 
potent inducers of a Th1-type response [34]. In experiment 1, the O-Ags+TLR group exhibited 422 
hallmarks of a strongly Th1-biased immunity. The more balanced Th1/Th2 immunity elicited 423 
through O-Ags was more favorable for successful pregnancy. In addition, the complete absence 424 
of protection in mice immunized with OprI-fused ovalbumin, and our previous studies employing 425 
a chimeric N. caninum antigen (NcMIC1-3-R;) [18], showed that the protection achieved with the 426 
polyvalent O-Ags formulation employed here was clearly antigen-dependent.  427 
OprI-PDI elicited the strongest humoral immune response. PDI-specific IgG levels were 428 
elevated already prior to challenge, before and after mating. However, further investigation of 429 
anti-PDI antibody levels at 9dpi in pregnant mice then demonstrated a decrease (or a lack of 430 
boost) of antibody levels. This was observed in experiments 1 and 2, but mice could be 431 
individually tracked only in experiment 2. In contrast, sera of only few mice had detectable 432 
antibodies directed against ROP2 and ROP40 when assessed by ELISA prior to challenge and at 433 
9dpi., and this low response was confirmed by Western blotting using sera from experiment 1. 434 
Nevertheless, immunoblotting confirmed specific recNcROP2 and recNcROP40 antibody 435 
responses, since a signal against recNcROP2 was detected at 9dpi in both O-Ags and O-436 
Ags+TLR vaccinated groups, with no signal in the C+ group. RecNcROP40 was also detected 437 
slightly by both vaccinated groups at pre-challenge phase, boosting at 9dpi in the O-Ags+TLR 438 
group.  439 
The decrease, or lack of boost, of anti-PDI antibody levels was observed only in pregnant 440 
animals. The lack of PDI-specific antibody boost after the third immunization in the vaccinated 441 
pregnant mice was only observed in pregnant animals. This indicates immune modulation due to 442 
the pregnancy, but it is unclear how this affects the overall protectivity of the vaccine 443 
formulation. An inverse correlation between anti-PDI-antibody levels and protection against 444 
cerebral infection could be observed in dams. Those pregnant mice with a slightly increased anti-445 
PDI antibody levellevels between the pre-challenge and 9 dpi were those exhibiting high parasite 446 
burden and clinical signs score afterwards. Conversely, those dams showing the strongest drop of 447 
antibody levels between these two time-points were those with lowest parasite burden afterwards. 448 
However, in the pups, no correlation with vertical transmission was detected. Whether the 449 
impairment in anti-PDI antibodies boost was a consequence of an early control of parasite 450 
replication or a requisite for improved protection is not clear. A study on N. caninum profilin 451 
vaccinated mice [32] also reported on a drop of profilin-specific antibody titers shortly after 452 
challenge, and levels recovered at 21dpi.  It was suggested that antibodies were being consumed 453 
by playing an active role against the infection [35]. However, only non-pregnant animals were 454 
assessed, and in our study non-pregnant mice actually showed a strong boost of antibody levels 455 
between pre-challenge and 9 dpi, and we did not note a correlation between antibody levels at 456 
9dpi and cerebral parasite burden. Thus, the differential antibody kinetics observed here is likely 457 
to be a consequence of a pregnancy-associated phenomenon. Antibody levels are also altered 458 
during the course of N. caninum infection in cattle. In naturally infected heifers, antibody 459 
fluctuations occurring between 90 and 240 days of gestation were shown to be associated with a 460 
higher probability of vertical transmission [36, 37]. Cows that aborted also showed more 461 
pronounced fluctuations and overall higher antibody levels, especially between months 3 and 8 of 462 
gestation, compared to non-aborting cows [38]. Whether the vaccine-associated drop in antibody 463 
levels in dams compared to non-pregnant mice is a reflection ofreflects a downregulation of total 464 
blood immunoglobulins during pregnancy needs to be further investigated. In humans, an overall 465 
reduction of total IgG and IgM was observed in healthy pregnant women compared to healthy 466 
non-pregnant women [39]. 467 
In experiment 2, cytokine levels were studied at 9dpi in peripheral blood samples, and at 468 
30dpi for non-pregnant mice and 43dpi for dams by analyzing splenocyte recall responses after 469 
stimulation with crude N. caninum extracts. Moreover, all mice were individually tracked. At 470 
9dpi, IFNγ blood levels were lower in O-Ags vaccinated mice compared to the C+ group, in both 471 
pregnant and non-pregnant mice. However, at chronic phase, namely at 43dpi, when IFNγ levels 472 
were measured in culture supernatants of stimulated splenocytes, this effect was not observed. 473 
Splenocytes from vaccinated dams with lower vertical transmission rates tended to produce more 474 
IFNγ, thus the correlation between IFNγ levels and vertical transmission was inverted. When 475 
splenocytes from non-pregnant mice were stimulated and supernatants assessed for IFNγ, higher 476 
levels were recorded in the O-Ags vaccinated group compared to C+ group. It was shown earlier 477 
that in N. caninum infected mice IFNγ levels reach a peak around 10dpi [40], which is in 478 
accordance with the highest IFNγ levels observed in our C+ group at 9 dpi. We suggest that the 479 
down-regulation of IFNγ levels at 9dpi in O-Ags mice may have contributed to the reduction of 480 
cerebral infection in non-pregnant mice and of vertical transmission in dams. A similar 481 
interesting pattern of IFNγ responses was already described [41]. Dams primo-infected during 482 
pregnancy (corresponding to our C+ group) showed increased production of IFNγ compared to 483 
non-pregnant mice peaking at 11dpi. However, those dams which were protected against vertical 484 
transmission by being infected before breeding showed a decreasing kinetic of IFNγ levels along 485 
the pregnancy and increasing at delivery [41]. Further investigations should be carried out to 486 
elucidate the role of IFNγ induced by protective vaccine formulations and how this IFNγ 487 
response is affected during pregnancy. 488 
In summary, these vaccination studies in a neosporosis mouse model have shown that 489 
promising efficacy against congenital and cerebral neosporosis can be achieved by immunization 490 
with a polyvalent combination vaccine composed of recombinant NcPDI, NcROP2 and 491 
NcROP40, all three fused to the TLR2-ligand OprI. This vaccine induced a balanced Th1/Th2 492 
immune response in adults, which reduced vertical transmission, but was not highly efficacious in 493 
preventing cerebral infection in dams. To the best of our knowledge, this is a major advance in 494 
terms of efficacy achieved with a recombinant vaccine formulation. Further studies should aim to 495 
optimize the dosage and the timing of immunizations, and it will be highly interesting to 496 
elucidate the immunological mechanisms that are responsible for the protective effects against 497 
vertical transmission.  498 
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Figure Legends 638 
 639 
Fig. 1Fig. 1. Schematic presentation of experiments 1 and 2. Female mice were immunized in 640 
two-week intervals, twice prior to mating (Imm. I; Imm. II), and a third time (Imm. III) shortly 641 
after mating. All mice were challenged by subcutaneous inoculation of 10
5
 N. caninum 642 
tachyzoites. Mice were closely monitored for clinical signs and mortality. Non-pregnant mice 643 
were euthanized on day 30 post-infection, dams and pups were euthanized on days 43-45 post-644 
infection. Immunoglobulins (Igs) and/or cytokine responses were analyzed at different time-645 
points for experiment 1 and 2: PrCh-1= Pre-challenge time-point experiment 1 (only Igs 646 
analyzed); PrCh-2 = Pre-challenge time-point experiment 2 (only Igs analyzed); PstCh-pm = 647 
Post-challenge “post-mating” time-point (Igs analyzed for experiment 1, both Igs and cytokines 648 
for experiment 2); PstCh-NonPreg = Post-challenge “non-pregnant mice” time-point (Igs 649 
analyzed for experiment 1, both Igs and cytokines for experiment 2); PstCh-D = Post-challenge 650 
“dams” time-point (Igs analyzed for experiment 1, both Igs and cytokines for experiment 2).W = 651 
time-point of oestrus synchronization (Whitten effect); M = mating  652 
 653 
Fig. 2. SDS-PAGE and dendritic cell stimulation assays. (A) SDS-PAGE and Comassie staining 654 
of OprI-PDI, OprI-ROP2, OprI-ROP40 and OprI-OVA, all expressed in E. coli and purified as 655 
described in materials and methods. For each protein, 3, 1 and 0.3 µg (from left to right) was 656 
loaded. M = molecular weight marker. (B) TNF-alpha levels in medium supernatants following 657 
stimulation of mouse bone marrow-derived dendritic cells with 1 or 5 µg of OprI-PDI, OprI-658 
ROP2 or OprI-ROP40, compared with TNF-alpha-levels in supernatants of DC cultures 659 
stimulated with the corrersponding non-OprI-antigens. Each assay was done in triplicates, and the 660 
error bar indicates the standard error of the mean (SEM). 661 
Fig. 2. Timeline of experiments 1 and 2. Female mice were immunized in two-week intervals, 662 
twice prior to mating (Imm. I; Imm. II), and a third time (Imm. III) after mating. All mice were 663 
challenged by subcutaneous inoculation of 10
5
 N. caninum tachyzoites. Mice were closely 664 
monitored for clinical signs and mortality. Non-pregnant mice were euthanized on 30 days post-665 
infection, dams and pups were euthanized on 43-45 days post-infection. W = time-point of 666 
oestrus synchronization (Whitten effect); M = mating; PrCh-1= Pre-challenge time-point 667 
experiment 1; PrCh-2 = Pre-challenge time-point experiment 2; PstCh-pm = Post-challenge 668 
“post-mating” time-point; PstCh-NonPreg = Post-challenge “non-pregnant mice” time-point; 669 
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PstCh-D = Post-challenge “dams” time-point; Igs = immunoglobulins; Bold arrows indicate time-670 
points of immune response analysis. 671 
 672 
Fig. 3. Kaplan Meier survival curves of pups from experiment 1 (A) and experiment 2 (B). 673 
 674 
Fig. 4. Cerebral parasite burden measured by real-time PCR in dams from experiment 1 (A) and 675 
2 (B) at 40-44 dpi, and from non-pregnant mice from experiment 2 at 30 dpi (C). Experiment 1 is 676 
not shown since only one mouse from the O-Ags group remained non-pregnant. (D) shows the 677 
clinical signs score of non-pregnant mice in experiment 2. 678 
 679 
Fig. 5. Humoral immune responses against recombinant antigens. A) Western blot analysis of 680 
pooled sera obtained from experiment 1. Recombinant ROP2 (rROP2) (MW = 41 kDa) and 681 
rROP40 (MW = 49 kDa) were separated by SDS-PAGE, blotted onto nitrocellulose, and rROP2- 682 
and rROP40-specific IgG were detected by immunoblotting in mouse sera obtained at the pre-683 
challenge phase prior to mating (PrCh-1) and at 9 dpi coinciding with days 14-16 of pregnancy 684 
(PstCh-pm.). “+” depicts a positive control serum from a mouse that was chronically infected 685 
with N. caninum. 1, 2, and 3 strips represent dilutions 1:50, 1:200 and 1:800 of pooled sera. 686 
Arrowheads indicate the location of recombinant proteins. (B) ELISA-based detection and 687 
quantification of PDI-specific IgG1 and IgG2a levels in experiment 1. PDI-specific antibodies in 688 
mice vaccinated with O-Ags and O-Ags+TLR ligands collected at the pre-challenge phase prior 689 
to mating (PrCh-1) and at 9 dpi coinciding with days 14-16 post mating (PstCh-pm). (C) Ratio of 690 
IgG1:IgG2a. Dots represent individual values of 4 randomly chosen mice euthanized at PrCh-1 691 
and 3 pregnant mice randomly chosen to be euthanized at PstCh-pm. Horizontal lanes represent 692 
the median in each group. 693 
 694 
Fig. 6. IgG1 and IgG2a antibodies against soluble N. caninum extract in sera from mice from 695 
experiment 2. Sera were from vaccinated groups (O-Ags, O-Ags+TLR, O-Ova) and the non-696 
vaccinated and infected group (C+) collected at the end of the experiment (30 dpi for non-697 
pregnant mice and 40 dpi for dams). (*) indicates statistically significant differences (U Mann-698 
Whitney U test, P<0.05). 699 
 700 
Fig. 7. Cytokine levels measured in blood samples obtained at 9 dpi coinciding with days 14-16 701 
post-mating (PstCh-pm.) in experiment 2. Boxes represent median, 25
th
 and 75
th
 percentiles; 702 
whiskers and individual points represent extreme values by Tukey method. (*) indicates 703 
statistically significant differences, Kruskal-Wallis, P <0.05.  704 
 705 
Fig. 8. Cytokine responses after splenocyte restimulation in vitro with N. caninum crude extract 706 
in dams (40 dpi) and non-pregnant (30 dpi) mice at the end of experiment 2. Boxes represent 707 
median, 25
th
 and 75
th
 percentiles; whiskers and individual points represent extreme values by 708 
Tukey method. (*) and (**) show Kruskal-Wallis, P < 0.05 and P < 0.01 statistically significant 709 
differences, respectively, compared to C- group. 710 
 711 
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 713 
Table 1. Outcome of Neospora caninum infection in dams and pups in experiments 1 and 2. 714 
Group Experiment Fertilitya 
No. 
damsb 
Litter 
sizec 
Neonatal 
mortalityd 
Postnatal 
mortalitye 
Postnatal 
survivalf 
Median 
survival 
timeg 
Vertical 
transmissionh 
O-Ags Exp. 1 
14/15 
(93.3%)  
11 5.2 
8/57 
(14.0%) 
32/49 
(65.3%) 
17/49 
(34.7%) 
18 
39/49 
(79.6%) 
O-Ags Exp 2. 
9/20 
(45%) 
9 6.6 
5/59 
(8.5%) 
31/54 
(57.4%) 
23/54 
(42.6%) 
21.5 
35/54 
(64.8%) 
O-
Ags+TLR 
Exp. 1 
9/16 
(56.3%) 
6 5.7 
3/34 
(8.8%) 
26/31 
(83.9%) 
5/31 
(16.1%) 
16 
28/31 
(90.3%) 
O-OVA Exp. 2 
9/20 
(45%) 
9 6.3 
3/57 
(5.3%) 
47/54 
(87.0%) 
7/54 
(12.9%) 
16.5 
48/54 
(88.9%) 
C+ Exp. 1 
11/20 
(55%) 
8 5.6 
14/45 
(31.1%) 
28/31 
(90.3%) 
3/31 
(9.7%) 
15 
30/31 
(96.8%) 
C+ Exp. 2 
14/20 
(70%) 
14 6.4 
6/89 
(6.7%) 
70/83 
(84.3%) 
13/83 
(15.7%) 
16 74/83 (89.2) 
C- Exp. 1 
11/16 
(68.8%) 
8 5.9 
14/47 
(29.8%) 
0/33  
(0%) 
33/33 
(100%) 
Undef. 0/33 (0%) 
C- Exp. 2 
10/20 
(50%) 
10 6.2 
2/62 
(3.2%) 
0/60  
(0%) 
60/60 
(100%) 
Undef. 0/60 (0%) 
a
 Proportion of pregnant mice per group (%) 715 
b
 In experiment 1, three pregnant mice were excluded because they were euthanized before birth for blood 716 
sampling. 717 
c
 Number of delivered pups per dam 718 
d
 Proportion of pups born dead or that died within the first 2 days post-partum (%) 719 
e
 Proportion of pups died from day 3 to 30 post-partum (%) 720 
f
 Proportion of survival pups at day 30 post-partum (%) 721 
g
 Day post-partum at which 50% of pups were dead 722 
h
 Proportion of Neospora caninum-PCR positive surviving pups plus those which died from day 3 post-partum 723 
(dead pups from day 3 post-partum are considered N. caninum-PCR positive as previously shown (Dellarupe et 724 
al., 2014)). 725 
Undef.: undefined, no pup mortality.  726 
 727 
 728 
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